Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Eli Lilly And EVA Pharma Entered Into An Agreement To Expand Access To Baricitinib To An Estimated 20,000 People In 49 Low- To Middle-income Countries In Africa By 2030

Author: Benzinga Newsdesk | September 04, 2024 06:06am

Discovered By Incyte And Licensed To Lilly, Baricitinib Is For The Treatment Of Rheumatoid Arthritis, Alopecia Areata, Atopic Dermatitis, And Covid-19.

Posted In: INCY LLY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist